China's National Medical Products Administration has approved the clinical trials for an inhaled COVID-19 vaccine co-developed by domestic firm CanSino Biologics and the Institute of Military Medicine under the Academy of Military Sciences, the company said in a filing published on the website of HKEx on Tuesday.

The clinical trial application got the green light on Monday. 

The vaccine's safety and efficacy remain "subject to confirmation" in trials, said the company.